Added to YB: 2024-04-04
Pitch date: 2024-03-02
ARGX [bullish]
argenx SE
+110.27%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Market Cap
EUR 55.4B
Pitch Price
EUR 358.20
Price Target
N/A
Dividend
N/A
EV/EBITDA
72.01
P/E
38.93
EV/Sales
14.00
Sector
Biotechnology
Category
growth
Show full summary:
TimesSquare U.S. Mid Cap Growth Strategy Added to Portfolio Holding: argenx SE
ARGX: Immunology co focused on autoimmune diseases. Q3 rev beat, loss < est. Vyvgart sales grew, beating projections. Mgmt detailed pipeline & trials. Advance SC trial for advanced immune thrombocytopenia missed endpoints, causing -23% pullback. We added to our position.
Read full article (1 min)